Explore Business Standard
Jubilant HollisterStier LLC, an arm of Jubilant Pharmova Ltd, will invest USD 300 million by FY28 in the US to double its sterile injectable manufacturing capacity, with President Donald Trump's tariffs accelerating its original plans, company CEO - CDMO Sterile Injectables, Chris Preti, said on Friday. The company has launched its new sterile fill and finish line -- the third at its Spokane manufacturing facility in Washington, US, set up at an investment of USD 132 million, Preti told PTI. "Our overall investment is almost USD 300 million at our Spokane facility. This is the first of the two phases ... This USD 132 million is phase one, which is our third line," he said. Preti further said, "This will bring an additional 50 per cent of capacity in the US that is available now and then, the additional investment, totaling USD 300 million in all, will be actually completed by the end of fiscal year 2028 which will bring on another 50 per cent of additional capacity." On the company
Leading QSR chain operator Jubilant Foods is looking to expand its pizza chain Domino's presence to 3,000 stores and around 250 outlets of US-based Fried Chicken brand Popeyes over the next three years, its CEO and MD Sameer Khetarpal said on Thursday. The Jubilant Bhartia Group company is focusing on smaller tier III towns and entering into new markets for Domino's. For Popeyes, it will focus on metro and tier II cities. "We will be growing in both brands. I think, our focus and priority is Popeyes. We believe Popeyes will grow faster than the other brands," Khetarpal told PTI. Currently, Jubilant Foods Ltd (JFL) operates around 2,100 Domino's outlets, the second largest network of the US-based multinational pizza restaurant chain globally. For Popeyes, Khetarpal said JFL is currently operating around 60 stores and will keep on adding up to 50 stores every year and have nearly 200 to 250 stores over the three years. "We go tier I, tier II for sure like we already are present in
Specialty chemicals and life science ingredient maker Jubilant Ingrevia on Tuesday reported an increase of 54 per cent in its net profit at Rs 59.38 crore for the third quarter ended December 2024. It had posted a net profit of Rs 38.56 crore in the October-December quarter a year ago, according to a regulatory filing from the Jubilant Bhartia Group firm. Its sales were up 8.91 per cent to Rs 1,046.06 crore during the quarter under review as compared to Rs 960.45 crore in the corresponding period a year ago. Total expenses of Jubilant Ingrevia in the December quarter were up 5.48 per cent to Rs 970.63 crore. Jubilant Ingrevia's total income, including other income, was Rs 1,056.20 crore, up 8.3 per cent year-on-year in the December quarter. Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said the significant year-on-year growth for this quarter is "attributed to the enhanced performance of our Specialty Chemicals and Nutrition businesses, as well as to the benefits derived